The University of Texas MD Anderson Cancer Center and Pfizer Inc. today announced that they have entered into a clinical collaboration to study novel combinations of three Pfizer investigational immuno-oncology therapies and other Pfizer agents in the treatment of various solid tumors and hematologic malignancies.
“This alliance aims to define patients with solid tumors who may benefit from immunotherapy and to develop...
Diet and exercise may improve treatment outcomes in pediatric cancer patients, according to a study at The University of Texas MD Anderson...
Participating in twice-weekly practice of Tibetan yoga may reduce sleep disturbances and improve sleep quality in breast cancer patients receiving...
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University of Texas MD Anderson Cancer Center with proposed guidelines for systematically dealing with the toxicities of these drugs.
Their work, published today in Nature Reviews Clinical Oncology, confronts the two...
The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on...
As the official cancer center of the PGA TOUR, The University of Texas MD Anderson Cancer Center will provide complimentary skin cancer screenings...
William Atkinson is the 2017 recipient of the Julie and Ben Rogers Award for Excellence in Administration at The University of Texas MD Anderson...
Through dedicated teamwork, strategic planning and the support of its internal and external communities, The University of Texas MD Anderson...
The University of Texas MD Anderson Cancer Center brings its signature Making Cancer History® Seminar to Atlanta for the third time, 8:30-...